Serum seleno-proteins status for colorectal cancer screening explored by data mining techniques - a multidisciplinary pilot study

Microchemical Journal

Volumn 105, Issue , 2012, Pages 124-132

  Roman, Marco ^a   Jitaru, Petru ^b   Agostini, Marco ^c,d,e   Cozzi, Giulio ^a   Pucciarelli, Salvatore ^c   Nitti, Donato ^c   Bedin, Chiara ^c   Barbante, Carlo ^a,f,g  

^a CNR   (Italy)

^b INSTITUT POLYTECHNIQUE LASALLE BEAUVAIS   (France)

^c UNIVERSITY OF PADOVA   (Italy)

^d HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^e Istituto di Ricerca Pediatrica Città della Speranza   (Italy)

^f CA' FOSCARI UNIVERSITY OF VENICE   (Italy)

^g ACCADEMIA NAZIONALE DEI LINCEI   (Italy)

Author keywords

Artificial neural networks; Classification trees; Colorectal cancer; Inductively coupled plasma mass spectrometry; Logistic regression analysis; Seleno proteins

Indexed keywords

EID: 84867840031     PISSN: 0026265X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.microc.2012.02.004     Document Type: Article

References (73)

1. Papp L.V., Lu J., Holmgren A., Khanna K.K. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid. Redox Signal. 2007, 9:775-806.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global Cancer Statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
3. Sciezka M., Danch A., Machalski M., Drozdz M. Plasma selenium concentration in patients with stomach and colon cancer in the upper silesia. Neoplasma 1997, 44:395-397.
4. Psathakis D., Wedemeyer N., Oevermann E., Krug F., Siegers C., Bruch H. Blood selenium and glutathione peroxidase status in patients with colorectal cancer. Dis. Colon Rectum 1998, 41:328-335.
5. Milde D., Novák O., Stuzka V., Vyslouzil K., Machácek J. Serum levels of selenium, manganese, copper, and iron in colorectal cancer patients. Biol. Trace Elem. Res. 2001, 79:107-114.
6. Clark L., Hixson L., Combs G., Reid M., Turnbull B., Sampliner R. Plasma selenium concentration predicts the prevalence of colorectal adenomatous polyps. Cancer Epidemiol. Biomarkers Prev. 1993, 2:41-46.
7. Russo M.W., Murray S.C., Wurzelmann J.I., Woosley J.T., Sandler R.S. Plasma selenium levels and the risk of colorectal adenomas. Nutr. Cancer 1997, 28:125-129.
8. Fernández-Bañares F., Cabré E., Esteve M., Mingorance M.D., Abad-Lacruz A., Lachica M., Gil A., Gassull M.A. Serum selenium and risk of large size colorectal adenomas in a geographical area with a low selenium status. Am. J. Gastroenterol. 2002, 97:2103-2108.
9. Connelly-Frost A., Poole C., Satia J.A., Kupper L.L., Millikan R.C., Sandler R.S. Selenium, Apoptosis, and Colorectal Adenomas. Cancer Epidemiol. Biomarkers Prev. 2006, 15:486-493.
10. Dworkin B.M., Rosenthal W.S., Mittelman A., Weiss L., Applehee-Brady L., Arlin Z. Selenium status and the polyp-cancer sequence: a colonoscopically controlled study. Am. J. Gastroenterol. 1988, 83:748-751.
11. Nelson R.L., Davis F.G., Sutter E., Kikendall J.W., Sobin L.H., Milner J.A., Bowen P.E. Serum selenium and colonic neoplastic risk. Dis. Colon Rectum 1995, 38:1306-1310.
12. Early D.S., Hill K., Burk R., Palmer I. Selenoprotein levels in patients with colorectal adenomas and cancer. Am. J. Gastroenterol. 2002, 97:745-748.
13. Wallace K., Byers T., Morris J.S., Cole B.F., Greenberg E.R., Baron J.A., Gudino A., Spate V., Karagas M.R. Prediagnostic serum selenium concentration and the risk of recurrent colorectal adenoma: a nested case-control study. Cancer Epidemiol. Biomarkers Prev. 2003, 12:464-467.
14. Gromadzińska J., Reszka E., Bruzelius K., Wasowicz W., Åkesson B. Selenium and cancer: biomarkers of selenium status and molecular action of selenium supplements. Eur. J. Nutr. 2008, 47:29-50.
15. Taylor P.R., Greenwald P. Nutritional interventions in cancer prevention. J. Clin. Oncol. 2005, 23:333-345.
16. Lopez-Saez J.B., Senra-Varela A., Pousa-Estevez L. Selenium in breast cancer. Oncology 2003, 64:227-231.
17. Hernández-Caraballo E.A., Rivas F., Pérez A.G., Marcó-Parra L.M. Evaluation of chemometric techniques and artificial neural networks for cancer screening using Cu, Fe, Se and Zn concentrations in blood serum. Anal. Chim. Acta 2005, 533:161-168.
18. Thomson C.D. Selenium speciation in human body fluids. Analyst 1998, 123:827-831.
19. Burk R.F., Hill K.E., Montley A.K. Plasma selenium in specific and non-specific forms. Biofactors 2001, 14:107-114.
20. Dumont E., Vanhaecke F., Cornelis R. Selenium speciation from food source to metabolites: a critical review. Anal. Bioanal. Chem. 2006, 385:1304-1323.
21. Selenium: Its molecular biology and role in human health 2006, Springer-Verlag, New York. D.L. Hatfield, M.J. Berry, V.N. Gladyshev (Eds.).
22. Reid M.E., Duffield-Lillico A.J., Sunga A., Fakih M., Alberts D.S., Marshall J.R. Selenium supplementation and colorectal adenomas: an analysis of the nutritional prevention of cancer trial. Int. J. Cancer 2006, 118:1777-1781.
23. Kumar A., Sharma S., Pundir C.S., Sharma A. Decreased plasma glutathione in cancer of the uterine cervix. Cancer Lett. 1995, 94:107-111.
24. Persson-Moschos M., Stavenow L., Åkesson B., Lindgärde F. Selenoprotein P in plasma in relation to cancer morbidity in middle-aged Swedish men. Nutr. Cancer 2000, 36:19-26.
25. Silvera S., Rohan T. Trace elements and cancer risk: a review of the epidemiologic evidence. Cancer Causes Control 2007, 18:7-27.
26. Bellazzi R., Zupan B. Predictive data mining in clinical medicine: current issues and guidelines. Int. J. Med. Inform. 2008, 77:81-97.
27. de Noo M.E., Mertens B.J.A., Özalp A., Bladergroen M.R., van der Werff M.P.J., van de Velde C.J.H., Deelder A.M., Tollenaar R.A.E.M. Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur. J. Cancer 2006, 42:1068-1076.
28. Selaru F.M., Xu Y., Yin J., Zou T., Liu T.C., Mori Y., Abraham J.M., Sato F., Wang S., Twigg C., Olaru A., Shustova V., Leytin A., Hytiroglou P., Shibata D., Harpaz N., Meltzer S.J. Artificial neural networks distinguish among subtypes of neoplastic colorectal lesions. Gastroenterology 2002, 122:606-613.
29. Frederiksen C.M., Knudsen S., Laurberg S., Ørntoft T.F. Classification of Dukes' B and C colorectal cancers using expression arrays. J. Cancer Res. Clin. Oncol. 2003, 129:263-271.
30. Kim H., Suk W.N., Rhee H., Long S.L., Hyun J.K., Kwi H.K., Nam K.K., Song J., Liu E.T.B. Different gene expression profiles between microsatellite instability-high and microsatellite stable colorectal carcinomas. Oncogene 2004, 23:6218-6225.
31. Mori Y., Selaru F.M., Sato F., Yin J., Simms L.A., Xu Y., Olaru A., Deacu E., Wang S., Taylor J.M., Young J., Leggett B., Jass J.R., Abraham J.M., Shibata D., Meltzer S.J. The impact of microsatellite instability on the molecular phenotype of colorectal tumors. Cancer Res. 2003, 63:4577-4582.
32. Smith F.M., Gallagher W.M., Fox E., Stephens R.B., Rexhepaj E., Petricoin E.F., Liotta L., Kennedy M.J., Reynolds J.V. Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann. Surg. 2007, 245:259-266.
33. Cardoso J., Boer J., Morreau H., Fodde R. Expression and genomic profiling of colorectal cancer. Biochim. Biophys. Acta Rev. Cancer 2007, 1775:103-137.
34. Jitaru P., Cozzi G., Gambaro A., Cescon P., Barbante C. Simultaneous speciation analysis of glutathione peroxidase, selenoprotein P and selenoalbumin in human serum by tandem anion exchange-affinity HPLC and on-line isotope dilution ICP-quadrupole MS. Anal. Bioanal. Chem. 2008, 391:661-669.
35. Cancer Staging Manual A.J.C.C. 2002, Springer-Verlag, New York, US. S. Edge, D. Byrd, C. Compton, A. Fritz, F. Greene, A. Trotti (Eds.).
36. Deschoolmeester V., Baay M., Specenier P., Lardon F., Vermorken J.B. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist 2010, 15:699-731.
37. Shin U., Yu C., Kim J., Kim T., Lim S.-B., Yoon S., Yoon Y., Kim C., Kim J. Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis. Ann. Surg. Oncol. 2011, 18:2232-2239.
38. Jass J.R., Love S.B., Northover J.M.A. A new prognostic classification of rectal cancer. Lancet 1987, 329:1303-1306.
39. Talbot I.C., Ritchie S., Leighton M.H., Hughes A.O., Bussey H.J.R., Morson B.C. The clinical significance of invasion of veins by rectal cancer. Br. J. Surg. 1980, 67:439-442.
40. Lindor N.M., Burgart L.J., Leontovich O., Goldberg R.M., Cunningham J.M., Sargent D.J., Walsh-Vockley C., Petersen G.M., Walsh M.D., Leggett B.A., Young J.P., Barker M.A., Jass J.R., Hopper J., Gallinger S., Bapat B., Redston M., Thibodeau S.N. immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J. Clin. Oncol. 2002, 20:1043-1048.
41. Ogino S., Kawasaki T., Kirkner G., Ohnishi M., Fuchs C. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer 2007, 7:72.
42. Umar A., Boland C.R., Terdiman J.P., Syngal S., Chapelle A.d.l., Rüschoff J., Fishel R., Lindor N.M., Burgart L.J., Hamelin R., Hamilton S.R., Hiatt R.A., Jass J., Lindblom A., Lynch H.T., Peltomaki P., Ramsey S.D., Rodriguez-Bigas M.A., Vasen H.F.A., Hawk E.T., Barrett J.C., Freedman A.N., Srivastava S. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst. 2004, 96:261-268.
43. Half E., Bercovich D., Rozen P. Familial adenomatous polyposis. Orphanet. J. Rare Dis. 2009, 4:22.
44. Epidemiology and medical statistics. Handbook of statistics 2008, 852. Elsevier, Amsterdam, The Nederlands. C.R. Rao, J.P. Miller, D.C.R. Rao (Eds.).
45. Kleinbaum D.G., Klein M. Logistic Regression 2002, Springer-Verlag, New York. 2 ed.
46. Rokach L., Maimon O. Data Mining with Decision Trees 2008, World Scientific Publishing, Singapore.
47. Quinlan J.R. C4.5: programs for machine learning 1993, Morgan Kaufmann Publishers Inc, San Francisco, CA, USA.
48. Begg R., Kamruzzaman J., Sarkar R. Neural Networks in Healthcare: Potential and Challenges 2006, Idea Group Publishing, London, UK.
49. Bishop C.M. Neural Networks for Pattern Recognition 2005, Oxford University Press, Oxford, UK.
50. Fawcett T. An introduction to ROC analysis. Pattern Recognit. Lett. 2006, 27:861-874.
51. Hanley J.A., McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983, 148:839-843.
52. Jacobson G.A., Narkowicz C., Tong Y.C., Peterson G.M. Plasma glutathione peroxidase by ELISA and relationship to selenium level. Clin. Chim. Acta 2006, 369:100-103.
53. Chan A.K., Wong A., Jenken D., Heine J., Johnson D., Buie D. Post-treatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiation. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61:665-677.
54. Wiesner G.L., Slavin T.P., Barnholtz-Sloan J.S. Colorectal Cancer. Essentials of Genomic and Personalized Medicine 2010, 457-476. Academic Press, San Diego. S.G. Geoffrey, F.W. Huntington (Eds.).
55. Decensi A., Costa A. Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer. Eur. J. Cancer 2000, 36:694-709.
56. Ransohoff D.F. Colon Cancer Screening in 2005: Status and Challenges. Gastroenterology 2005, 128:1685-1695.
57. Gupta A.K., Brenner D.E., Turgeon D.K. Early detection of colon cancer: new tests on the horizon. Mol. Diagn. Ther. 2008, 12:77-85.
58. Reilly C. Selenium in food and health 2006, Springer-Verlag, New York. 2nd ed.
59. Burk R., Hill K. Selenoprotein P: an extracellular protein with unique physical characteristics and a role in selenium homeostasis. Annu. Rev. Nutr. 2005, 25:215-235.
60. Schrauzer G.N. Selenomethionine: a review of its nutritional significance, metabolism and toxicity (Reprinted from vol 130, pg 1653, 2000). J. Nutr. 2002, 132:1653-1656.
61. Combs G.F., Gray W.P. Chemopreventive agents: selenium. Pharmacol. Ther. 1998, 79:179-192.
62. Peters U., Chatterjee N., Church T.R., Mayo C., Sturup S., Foster C.B., Schatzkin A., Hayes R.B. High serum selenium and reduced risk of advanced colorectal adenoma in a colorectal cancer early detection program. Cancer Epidemiol. Biomarkers Prev. 2006, 15:315-320.
63. Lloyd B., Lloyd R.S., Clayton B.E. Effect of smoking, alcohol, and other factors on the selenium status of a healthy population. J. Epidemiol. Community Health 1983, 37:213-217.
64. Persson-Moschos M., Alfthan G., Akesson B. Plasma selenoprotein P levels of healthy males in different selenium status after oral supplementation with different forms of selenium. Eur. J. Clin. Nutr. 1998, 52:363-367.
65. Allan C.B., Lacourciere G.M., Stadtman T.C. Responsiveness of selenoproteins to dietary selenium. Annu. Rev. Nutr. 1999, 19:1-16.
66. Duffield-Lillico A.J., Slate E.H., Reid M.E., Turnbull B.W., Wilkins P.A., Combs G.F., Park H.K., Gross E.G., Graham G.F., Stratton M.S., Marshall J.R., Clark L.C. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J. Natl. Cancer Inst. 2003, 95:1477-1481.
67. Francescato M.P., Furlan G., Tamer I., Grand E., Bernard B. Selenium status in healthy Italian adults. J. Hum. Nutr. Diet. 1991, 4:219-222.
68. Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura H., Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998, 58:3491-3494.
69. Hawkes W., Kelley D., Taylor P. The effects of dietary selenium on the immune system in healthy men. Biol. Trace Elem. Res. 2001, 81:189-213.
70. Ueno H., Murphy J., Jass J.R., Mochizuki H., Talbot I.C. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002, 40:127-132.
71. Kurt I., Ture M., Kurum A.T. Comparing performances of logistic regression, classification and regression tree, and neural networks for predicting coronary artery disease. Expert Syst. Appl. 2008, 34:366-374.
72. Azuaje F. Bioinformatics and Biomarker Discovery 2010, Wiley, Oxford, UK.
73. Jitaru P., Roman M., Barbante C., Vaslin-Reimann S., Fisicaro P. Challenges in the accurate speciation analysis of selenium in humans: first report on indicative levels of selenoproteins in a serum certified reference material for total selenium (BCR-637). Accredit. Qual. Assur. 2010, 15:343-350.